2-(2,3-dihydroindol-1-yl)-N,N-dimethylethanamine, often abbreviated as **2-DHI**, is a research chemical known for its **agonist activity at the 5-HT2A receptor**. This means that it can bind to and activate this specific type of serotonin receptor in the brain.
Here's why it's important for research:
* **Understanding 5-HT2A receptor function:** The 5-HT2A receptor is involved in a wide range of brain functions, including:
* **Perception:** It plays a role in sensory processing, including visual perception.
* **Cognition:** It's involved in learning, memory, and attention.
* **Mood and emotion:** It's implicated in anxiety, depression, and psychosis.
* **Sleep and appetite:** It influences sleep-wake cycles and food intake.
* **Developing new treatments:** Because of its role in these important brain functions, 5-HT2A receptor agonists and antagonists are being investigated for their potential therapeutic applications in conditions like:
* **Depression:** Some antidepressants are thought to work by modulating the 5-HT2A receptor.
* **Anxiety:** 5-HT2A antagonists are being explored as potential treatments for anxiety disorders.
* **Schizophrenia:** Certain atypical antipsychotics act as 5-HT2A antagonists.
* **Migraines:** 5-HT2A agonists are used as abortive treatments for migraines.
* **Investigating psychedelic effects:** 2-DHI, like other 5-HT2A receptor agonists, has been observed to possess **psychedelic effects**, which are often associated with altered perception and consciousness. This has sparked interest in its use as a research tool to study the mechanisms underlying psychedelic experiences and their potential therapeutic applications in conditions like addiction and end-of-life anxiety.
**Important Considerations:**
* 2-DHI is a research chemical and **not a drug approved for medical use**. Its safety and efficacy in humans are not fully established.
* Research involving 2-DHI should be conducted **ethically and responsibly** with appropriate safeguards in place.
**In summary, 2-DHI is a valuable research tool that helps scientists understand the complex role of the 5-HT2A receptor in the brain and its potential for therapeutic applications.** Its psychedelic properties further enhance its importance for investigating the mechanisms behind altered states of consciousness.
ID Source | ID |
---|---|
PubMed CID | 744368 |
CHEMBL ID | 422471 |
CHEBI ID | 114471 |
SCHEMBL ID | 7680979 |
Synonym |
---|
EU-0011905 |
CBDIVE_015848 |
smr000122729 |
MLS000523656 |
cid_744368 |
bdbm50150979 |
[2-(2,3-dihydro-indol-1-yl)-ethyl]-dimethyl-amine |
CHEMDIV2_000952 |
2-(2,3-dihydro-1h-indol-1-yl)-n,n-dimethylethanamine |
STK386817 |
CHEBI:114471 |
CHEMBL422471 , |
HMS1371L06 |
2-(2,3-dihydroindol-1-yl)-n,n-dimethylethanamine |
AKOS001675959 |
SCHEMBL7680979 |
HMS2370M08 |
AB00073802-01 |
Q27195874 |
[2-(2,3-dihydro-indol-1-yl)-ethyl]-dimethyl-amine, aldrichcpr |
Class | Description |
---|---|
indoles | Any compound containing an indole skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 44.6684 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 25.1189 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 39.8107 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 25.1189 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 19.9526 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 44.6684 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 22.3872 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 15.8489 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 12.7657 | 31.6228 | AID881 |
Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 25.1189 | 0.0063 | 8.2350 | 39.8107 | AID881 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
PTK2B protein tyrosine kinase 2 beta | Homo sapiens (human) | IC50 (µMol) | 6.4620 | 1.5370 | 4.0805 | 6.9220 | AID1641 |
estrogen receptor beta isoform 1 | Homo sapiens (human) | IC50 (µMol) | 0.0579 | 1.9109 | 8.3165 | 18.7976 | AID1060 |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 5.0000 | 0.0002 | 0.5229 | 10.0000 | AID238424 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | Kd | 0.2691 | 0.0004 | 2.4735 | 8.5114 | AID168920 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID238424 | Binding affinity against 5-hydroxytryptamine 6 receptor | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17 | Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors. |
AID168920 | Displacement of [3H]5-HT binding to serotonin receptor of rat fundus membranes | 1984 | Journal of medicinal chemistry, Jan, Volume: 27, Issue:1 | Synthesis and evaluation of a novel series of N,N-dimethylisotryptamines. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |